HUP0104844A3 - Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use - Google Patents

Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use

Info

Publication number
HUP0104844A3
HUP0104844A3 HU0104844A HUP0104844A HUP0104844A3 HU P0104844 A3 HUP0104844 A3 HU P0104844A3 HU 0104844 A HU0104844 A HU 0104844A HU P0104844 A HUP0104844 A HU P0104844A HU P0104844 A3 HUP0104844 A3 HU P0104844A3
Authority
HU
Hungary
Prior art keywords
inhibitor
mitoic
compositions containing
combination compositions
anticancer combination
Prior art date
Application number
HU0104844A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0104844A2 publication Critical patent/HUP0104844A2/hu
Publication of HUP0104844A3 publication Critical patent/HUP0104844A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HU0104844A 1998-12-22 1999-12-21 Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use HUP0104844A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10

Publications (2)

Publication Number Publication Date
HUP0104844A2 HUP0104844A2 (en) 2002-06-29
HUP0104844A3 true HUP0104844A3 (en) 2003-05-28

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104844A HUP0104844A3 (en) 1998-12-22 1999-12-21 Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use

Country Status (31)

Country Link
EP (1) EP1140291B1 (hu)
JP (1) JP2002532570A (hu)
KR (1) KR20010099877A (hu)
CN (1) CN1333698A (hu)
AP (1) AP2001002175A0 (hu)
AT (1) ATE310567T1 (hu)
AU (1) AU2203900A (hu)
BG (1) BG105715A (hu)
BR (1) BR9916839A (hu)
CA (1) CA2352326A1 (hu)
CZ (1) CZ20012139A3 (hu)
DE (1) DE69928568T2 (hu)
EA (1) EA200100687A1 (hu)
EE (1) EE200100339A (hu)
ES (1) ES2253928T3 (hu)
GE (1) GEP20043172B (hu)
HK (1) HK1042057A1 (hu)
HR (1) HRP20010473A2 (hu)
HU (1) HUP0104844A3 (hu)
ID (1) ID30250A (hu)
IL (1) IL143939A0 (hu)
IS (1) IS5969A (hu)
MA (1) MA26768A1 (hu)
NO (1) NO20013099L (hu)
NZ (1) NZ512859A (hu)
OA (1) OA11733A (hu)
PL (1) PL348326A1 (hu)
SK (1) SK8712001A3 (hu)
TR (1) TR200101871T2 (hu)
WO (1) WO2000037141A1 (hu)
YU (1) YU45401A (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
EP1676837A4 (en) * 2003-10-08 2008-09-10 Teijin Pharma Ltd METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
EA013212B1 (ru) 2004-10-20 2010-04-30 Лаборатуар Сероно Са 3-ариламинопиридиновые производные
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
CA2628039A1 (en) 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
EP2963114B1 (en) 2013-02-27 2018-12-12 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1998042830A2 (en) * 1997-03-21 1998-10-01 Board Of Regents, The University Of Texas System Noey2 gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Also Published As

Publication number Publication date
BR9916839A (pt) 2001-10-09
PL348326A1 (en) 2002-05-20
WO2000037141A9 (en) 2000-12-07
BG105715A (en) 2002-04-30
ES2253928T3 (es) 2006-06-01
SK8712001A3 (en) 2002-02-05
MA26768A1 (fr) 2004-12-20
EE200100339A (et) 2002-10-15
AP2001002175A0 (en) 2001-06-21
IL143939A0 (en) 2002-04-21
AU2203900A (en) 2000-07-12
KR20010099877A (ko) 2001-11-09
CA2352326A1 (en) 2000-06-29
ID30250A (id) 2001-11-15
NO20013099D0 (no) 2001-06-21
OA11733A (en) 2005-05-12
TR200101871T2 (tr) 2001-10-22
EP1140291B1 (en) 2005-11-23
NZ512859A (en) 2004-06-25
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
CN1333698A (zh) 2002-01-30
WO2000037141A1 (en) 2000-06-29
JP2002532570A (ja) 2002-10-02
DE69928568T2 (de) 2006-07-27
CZ20012139A3 (cs) 2002-01-16
EP1140291A1 (en) 2001-10-10
IS5969A (is) 2001-06-14
HK1042057A1 (zh) 2002-08-02
YU45401A (sh) 2004-07-15
EA200100687A1 (ru) 2001-12-24
DE69928568D1 (de) 2005-12-29
ATE310567T1 (de) 2005-12-15
NO20013099L (no) 2001-08-20
HRP20010473A2 (en) 2002-08-31

Similar Documents

Publication Publication Date Title
HUP0104844A3 (en) Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use
IL206621A0 (en) Caspase inhibitors and pharmaceutical compositions containing the same
HUP0001154A3 (en) 3-piperidyl-4-oxoquinazoline derivatives and medicincal compositions containing the same
IL115891A0 (en) Hemorrhoidial compositions and their use
HUP9801819A3 (en) Synergetic phytomicrobicide compositions and use thereof
GB9813271D0 (en) Composition and use
HUP0103562A3 (en) Novel compositions and use
ZA985096B (en) Composition compound and use
HUP0103845A3 (en) Disinfecting composition and its use
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
PL339175A1 (en) Synergetic compositions containing imazalyl and epoxyconazole
HUP0104852A3 (en) Oktahydro-pyrido-pyrazine derivatives and pharmaceutical compositions containing the same and their use
IL130093A0 (en) Hexanitrohexaazaisowurtzitane compositions and explosive compositions containing the same
GB9811168D0 (en) Direct hair-colouring compositions and the use thereof
HUP0003063A3 (en) Synergetic fungicidal composition and its use
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
GB9803232D0 (en) Compound composition and use
GB9803773D0 (en) Compositions and their use
GB9805172D0 (en) Composition and use
GB9706758D0 (en) Compositions and their use
ZA99976B (en) Pharmaceuticl and cosmetic compositions and their use.
ZA972566B (en) Polysorbate-containing compositions and their use against Helicobacter.
GB9722392D0 (en) Composition and use
GB9726811D0 (en) Compounds compositions and use
SG77680A1 (en) An epoxy-resin composition and use thereof